相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Clinical Neurology
Marton Konig et al.
Summary: This study aimed to characterize humoral immunity after mRNA-COVID-19 vaccination in people with multiple sclerosis (pwMS). The study found that patients treated with fingolimod or rituximab had reduced humoral immunity. It is important to carefully time the vaccinations for patients treated with rituximab.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Review
Clinical Neurology
David Baker et al.
Summary: This article examines the role of Sphingosine-one phosphate receptor (S1PR) modulators in the treatment of multiple sclerosis (MS) and their impact on SARS-CoV-2 vaccine and antiviral drug responses. It is found that the newer generation of S1PR modulators has better efficacy in generating antiviral responses. Further studies on the effectiveness of these modulators are necessary.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2023)
Article
Clinical Neurology
Emma C. Tallantyre et al.
Summary: The study found that some disease modifying therapies are associated with attenuated serological responses to SARS-CoV-2 vaccination in people with multiple sclerosis, including anti-CD20 monoclonal antibodies and fingolimod treatment. Additionally, vaccine type and treatment duration also impact vaccine response.
ANNALS OF NEUROLOGY
(2022)
Article
Microbiology
Esther Dawen Yu et al.
Summary: The study developed two pools of experimentally defined SARS-CoV-2 T cell epitopes to distinguish individuals with different SARS-CoV-2 infection and COVID-19 vaccine status with high accuracy. T cell responses effectively segregated breakthrough infections from vaccine responses, providing an important tool for longitudinal monitoring of vaccinations and establishing SARS-CoV-2 correlates of protection.
CELL HOST & MICROBE
(2022)
Article
Multidisciplinary Sciences
Leo Swadling et al.
Summary: Research suggests that some individuals can clear potential SARS-CoV-2 infection after exposure, with T cells playing a role in the process. Studying healthcare workers who tested negative for antibodies revealed that they had stronger and more diverse memory T cells, with a focus on RTC.
Article
Multidisciplinary Sciences
Jinyan Liu et al.
Summary: This study demonstrates that cellular immunity induced by current SARS-CoV-2 vaccines is highly conserved to the Omicron spike protein. Individuals vaccinated with Ad26.COV2.S or BNT162b2 vaccines showed durable spike-specific CD8(+) and CD4(+) T cell responses that were cross-reactive to both the Delta and Omicron variants, including in central and effector memory cellular subpopulations.
Article
Clinical Neurology
Manuela Altieri et al.
Summary: This study assessed the immune response to the COVID-19 vaccine in patients with multiple sclerosis (pwMS) treated with natalizumab (NTZ). The results showed that pwMS on NTZ developed and maintained a long-term humoral response after the COVID-19 vaccination, similar to healthy individuals. These findings are important for clinicians when counseling pwMS on COVID-19 vaccine timing and booster doses.
NEUROLOGICAL SCIENCES
(2022)
Review
Clinical Neurology
Manila Hada et al.
Summary: This study reviewed the risk of SARS-CoV-2 infection and severe COVID-19 outcomes in multiple sclerosis (MS) patients treated with approved therapies in the United States. The findings suggest that MS patients treated with anti-CD20 monoclonal antibodies may be at increased risk for severe COVID-19. Further monitoring is warranted due to the potential implications for public health, especially in subpopulations with impaired response to COVID-19 vaccines.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Carla Tortorella et al.
Summary: This study evaluated the immune-specific response after full SARS-CoV-2 vaccination in patients with multiple sclerosis (MS) treated with different disease-modifying drugs. The results showed that mRNA vaccines induced both humoral and cell-mediated specific immune responses against viral spike proteins in the majority of patients with MS. These findings have important implications for promoting vaccination in all MS patients.
Article
Multidisciplinary Sciences
Juliette Leon et al.
Summary: Through in vitro co-culture modeling, the study found that the interaction between infected epithelial cells and immunocytes in SARS-CoV-2 infection leads to immune dysregulation, which may be the root cause of the inflammatory malfunction in COVID-19.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Letter
Clinical Neurology
Recai Turkoglu et al.
Summary: This study found that patients with multiple sclerosis (MS) receiving fingolimod treatment had a weaker humoral response to SARS-CoV-2 vaccines. The longer the treatment duration, the lower the antibody levels. Therefore, patients under fingolimod treatment may require closer monitoring for COVID-19.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Livnat Brill et al.
Summary: The study found that multiple sclerosis patients treated with cladribine are able to develop antibody response to the SARS-CoV-2 vaccine. This is reassuring and important for both patients and physicians, and could help in developing consensus guidelines.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Afagh Garjani et al.
Summary: This study investigated the changes in SARS-CoV-2 infection risk among patients receiving disease-modifying therapies for multiple sclerosis (MS) after vaccination. The results showed that patients taking ocrelizumab or fingolimod had a lower level of protection from the SARS-CoV-2 vaccines compared to the general population.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Fereshteh Ghadiri et al.
Summary: In Iran, multiple sclerosis patients were among the first to receive the COVID-19 vaccine. After vaccination, there was a decrease in COVID-19 infection rate, but no significant difference in severe cases. The only significant predictor was a history of severe allergic reactions.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Immunology
Marco Iannetta et al.
Summary: This study analyzed the cell-mediated immune responses in multiple sclerosis patients who received the mRNA vaccine, revealing differences in antibody levels and peripheral blood lymphocyte counts among patients on different drug treatments.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Clinical Neurology
Roseanne Sullivan et al.
Summary: A descriptive analysis of COVID-19 infection in patients with multiple sclerosis receiving fingolimod or siponimod revealed that the risk of more severe COVID-19 in these patients seems to be similar to that reported in the general population and the MS population with COVID-19. However, limitations of spontaneous reporting, especially missing data, should be considered in the interpretation of these observations.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2022)
Article
Medicine, Research & Experimental
Joseph J. Sabatino et al.
Summary: A comprehensive comparison of the effects of MS DMTs on SARS-CoV-2 vaccine-specific immunity is needed, including quantitative and functional B and T cell responses.
Article
Rheumatology
Ingrid Jyssum et al.
Summary: This study investigates the humoral and cellular immune responses in rheumatoid arthritis patients treated with rituximab after receiving two or three doses of SARS-CoV-2 vaccines. The study finds that some patients do not have serological responses to two doses of the vaccine, but a third dose can enhance the cellular immune response. This is important for understanding the vaccine efficacy in immunocompromised patients.
LANCET RHEUMATOLOGY
(2022)
Article
Clinical Neurology
Livnat Brill et al.
Summary: This study aimed to evaluate the humoral and cellular response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with B-cell depletion, particularly those who had a weak response to initial vaccination. The study found that the antibody titers did not increase in patients who had a weak or no response after the initial vaccination following the third vaccine dose. However, in healthy controls and MS patients treated with B-cell depletion, cellular response significantly increased after the third dose of the vaccine.
ANNALS OF NEUROLOGY
(2022)
Article
Biochemistry & Molecular Biology
Venice Servellita et al.
Summary: A study on vaccinated individuals found that Delta breakthrough infection induced stronger neutralizing immunity against the wild-type virus compared to Omicron breakthrough infection. The reduced antibody response in Omicron breakthrough infections may be related to a higher proportion of asymptomatic or mild infections, leading to lower neutralizing immunity against the wild-type virus.
Article
Clinical Neurology
Sapir Dreyer-Alster et al.
Summary: This study evaluated the safety and immune response of a third dose of COVID-19 BNT162b2 vaccine in patients with multiple sclerosis (MS). The results showed that the third dose of the vaccine was safe for MS patients and did not increase the risk of relapse activity. Untreated patients and patients treated with vaccination-safe disease-modifying treatments showed a significant increase in immune response following the third dose of vaccination.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Hamza Mahmood Bajwa et al.
Summary: This study examined the humoral and cellular response in multiple sclerosis patients on anti-CD20 therapy after receiving the third dose of BNT162b2 mRNA SARS-CoV-2 vaccine. The results showed no significant increase in humoral or cellular response after the third vaccination. This suggests the need for clinical strategies to allow B-cell reconstitution before repeat vaccination or the provision of prophylactic monoclonal antibodies.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Mario Habek et al.
Summary: In patients with multiple sclerosis, those treated with ocrelizumab are less likely to develop humoral immunity after COVID-19 recovery or vaccination, but there is no difference in cellular immunity compared to other treatment groups. This suggests that pwMS still have a certain level of cellular immune protection even when receiving B-cell depleting therapy.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Ethel Ciampi et al.
Summary: Safety and effectiveness outcomes in MS patients receiving different DMT and SARS-CoV-2 vaccines are limited. Evidence suggests that mRNA vaccines have a higher humoral response rate compared to inactivated vaccines, while patients using antiCD20 therapies have a lower response rate.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Medicine, General & Internal
Maria Pia Sormani et al.
Summary: This study aimed to monitor the risk of breakthrough SARS-CoV-2 infection in patients with MS under different DMTs and identify correlates of reduced protection. The results showed that reduced levels of virus-specific humoral immune response were associated with an increased risk of breakthrough infection.
Article
Clinical Neurology
Gabriel Bsteh et al.
Summary: This study analyzed predictors of COVID-19 outcomes in individuals with multiple sclerosis, finding that the severity of the course primarily depends on a priori risk factors. Vaccination significantly reduces the risk of severe COVID-19 in individuals with multiple sclerosis.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Immunology
Trung The Tran et al.
Summary: Current diagnostic assays for monitoring COVID-19 vaccine efficacy measure the levels of antibodies against the receptor-binding domain of the ancestral virus. This study presents a new method using bead-based arrays and flow cytometry to measure antibody binding to spike proteins and receptor-binding domains from different variants. The results show that the levels of antibodies against the ancestral virus correlate with the levels of binding and neutralizing antibodies against different variants.
Article
Clinical Neurology
Irene Schiavetti et al.
Summary: Patients with multiple sclerosis treated with ocrelizumab and fingolimod have a higher risk of breakthrough SARS-CoV-2 infections, while the rate of severe infections is significantly lower in all disease-modifying therapy groups excluding ocrelizumab.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Maria P. Sormani et al.
Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.
ANNALS OF NEUROLOGY
(2021)
Article
Multidisciplinary Sciences
Katherine McMahan et al.
Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.
Article
Biochemistry & Molecular Biology
Petter Brodin
Summary: The severity of COVID-19 varies by sex and age, and is linked to comorbidities. Differences in immune reactions may go some way to explain this.
Article
Immunology
Ahya Ali et al.
Summary: This study focused on the humoral immune responses to COVID-19 mRNA vaccine in patients with central nervous system autoimmune demyelinating diseases, multiple sclerosis (MS) and neuromyelitis optica (NMO), who are on B-cell depleting therapies (BCDT) and other disease modifying therapies (DMTs). The results showed that among patients on BCDT, there was a lower positive antibody response to spike RBD compared to other groups. Immunological data revealed lower IgM baseline levels in patients on BCDT, along with lower CD19 and CD20 counts, which were associated with a negative spike RBD antibody response.
Review
Immunology
Zhao Zhao et al.
Summary: Fingolimod treatment in patients with multiple sclerosis is associated with a significant increase in infection risk, with a 16% higher risk compared to placebo and other active treatments. The risk is especially elevated for lower respiratory infections and herpes virus infections, and does not appear to be dose-dependent.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Sachin P. Gadani et al.
Summary: This study found robust T cell responses in individuals with multiple sclerosis on anti-CD20 therapies despite a reduced humoral response to SARS-CoV-2 vaccination. Follow-up studies are needed to determine if this translates to protection against COVID-19 infection.
Article
Clinical Neurology
Diego Centonze et al.
Summary: COVID-19 emerged in Wuhan, China in December 2019 and quickly spread globally, with over 132 million cases and 2.8 million deaths recorded to date. A massive vaccination campaign has been initiated worldwide since the end of 2020, although there are concerns among neurologists about the safety and efficacy of vaccination in multiple sclerosis patients on immunomodulatory or immunosuppressive therapies.
JOURNAL OF NEUROLOGY
(2021)
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Article
Clinical Neurology
Amber Salter et al.
Summary: This study examined outcomes and risk factors associated with COVID-19 clinical severity in a large, diverse cohort of North American patients with multiple sclerosis. The study found that ambulatory disability, older age, male sex, Black race, cardiovascular comorbidities, and recent corticosteroid use were associated with increased odds of worse clinical severity in MS patients with COVID-19. Knowledge of these risk factors may help improve the treatment and monitoring of these patients.
Review
Clinical Neurology
Maryam Sharifian-Dorche et al.
Summary: This study reviews the impact of COVID-19 on patients with demyelinating diseases of the central nervous system like Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD), finding no clear relationship between disease-modifying therapies (DMT) use and the course of COVID-19. Risk factors for severe COVID-19 included age, higher EDSS scores, cardiac comorbidities, and obesity. Despite infection risks, most patients chose to continue DMT due to concerns about relapse or worsened MS symptoms, with some immune response attenuation seen in patients on specific medications post-infection.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2021)
Review
Immunology
Hannah Kelly et al.
Summary: COVID-19 vaccination is recommended for multiple sclerosis patients, although different types of vaccines may have varying impacts on their efficacy. It is important to carefully select vaccines for these patients, as some treatments may affect vaccine responses. Avoiding vaccines that could impact vaccine efficacy is crucial in treated patients.
JOURNAL OF NEUROIMMUNOLOGY
(2021)
Review
Medicine, General & Internal
Marisa P. McGinley et al.
Summary: 3-The S1P signalling pathways play crucial roles in various diseases, with S1PRs being proposed as therapeutic targets, especially in multiple sclerosis where they reduce inflammatory cell migration by regulating lymphocyte levels. Further development of S1PR modulators for other indications is supported by preclinical evidence and ongoing clinical trials.
Article
Biochemistry & Molecular Biology
Sokratis A. Apostolidis et al.
Summary: Patients with multiple sclerosis on anti-CD20 monotherapy exhibit significantly reduced SARS-CoV-2-specific antibodies and memory B cells, while CD4(+) and CD8(+) T cells are robustly activated compared to healthy controls after receiving BNT162b2 or mRNA-1273 mRNA vaccination.
Article
Immunology
Kristen A. Earle et al.
Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.
Article
Clinical Neurology
Tim Spelman et al.
Summary: This study investigated the association between national differences in treatment strategies for RRMS and disability outcomes, finding that the Swedish treatment strategy was associated with reduced rates of disability worsening compared to the Danish strategy.
Letter
Clinical Neurology
Giulio Disanto et al.
Article
Clinical Neurology
Livnat Brill et al.
Summary: Patients with MS treated with ocrelizumab showed comparable SARS-CoV-2-specific T-cell responses with healthy controls but lower antibody response following vaccination. This study provides reassurance regarding the potential role of T cells in protection from severe disease and will aid in the development of consensus guidelines for MS treatment during the COVID-19 pandemic.
Article
Clinical Neurology
Maria Pia Sormani et al.
Summary: This study evaluated the impact of disease-modifying therapies on Covid-19 severity in patients with multiple sclerosis through a pooled-analysis of two large cohorts. The results showed that anti-CD20 therapies were significantly associated with severe Covid-19, while interferon indicated a decreased risk.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Article
Clinical Neurology
Gustavo Luna et al.
Review
Chemistry, Multidisciplinary
Yuan Huang et al.
ACTA PHARMACOLOGICA SINICA
(2020)
Article
Clinical Neurology
Amit Bar-Or et al.
Article
Medicine, General & Internal
J. William L. Brown et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2019)
Article
Immunology
Katja Thomas et al.
JOURNAL OF NEUROINFLAMMATION
(2017)
Article
Clinical Neurology
Jonatan Salzer et al.
Review
Biochemistry & Molecular Biology
Tobias Ruck et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2015)
Article
Clinical Neurology
G. Francis et al.
MULTIPLE SCLEROSIS JOURNAL
(2014)
Review
Clinical Neurology
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY
(2010)
